Core Viewpoint - Atos Group has received a confirmatory offer from the French State to acquire its Advanced Computing business, excluding Vision AI activities, for an enterprise value of €410 million, which includes €110 million in earn-outs based on profitability indicators for fiscal years 2025 and 2026 [2][8]. Group 1: Transaction Details - The enterprise value of €410 million reflects a revised valuation due to the exclusion of Vision AI activities, which were previously part of the transaction scope [3][8]. - The Advanced Computing business includes High-Performance Computing (HPC), Quantum, Business Computing, and Artificial Intelligence divisions, expected to generate approximately €0.8 billion in revenue in 2025 [3][8]. - The transaction is anticipated to close in 2026, pending regulatory approvals and completion of employee consultations [9]. Group 2: Vision AI Reorganization - Vision AI activities, which contributed to over one-third of the operating margin of the previously considered perimeter, will be repositioned within Eviden to form a new business unit focused on AI, Data, and Security [4][8]. - This new structure aims to enhance Atos Group's offerings in AI-powered video analytics for various applications, including safety and security [4]. Group 3: Board and Financial Outlook - The Board of Directors has welcomed the offer, confirming that the transaction terms are at fair market value based on an independent expert's report [5]. - The financial trajectory for Atos Group through 2028 remains unchanged despite the disposal of the Advanced Computing business, as presented during the Capital Markets Day [5]. Group 4: Company Overview - Atos Group is a global leader in digital transformation with approximately 72,000 employees and annual revenue of around €10 billion, operating in 68 countries [6]. - The company is recognized as the European leader in cybersecurity, cloud, and high-performance computing, committed to providing tailored AI-powered solutions across various industries [6].

Core Insights - Novartis announced positive topline results from the Phase III PSMAddition trial, demonstrating a significant benefit in radiographic progression-free survival (rPFS) for Pluvicto™ in combination with standard of care (SoC) compared to SoC alone in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) [2][4][7] Group 1: Trial Results - The PSMAddition trial met its primary endpoint with a statistically significant and clinically meaningful benefit in rPFS, along with a positive trend in overall survival (OS) [2][4] - The trial involved adult patients with PSMA-positive mHSPC, comparing the efficacy and safety of Pluvicto combined with SoC (androgen receptor pathway inhibitor therapy and androgen deprivation therapy) versus SoC alone [6][7] Group 2: Treatment Context - Most mHSPC patients eventually progress to metastatic castration-resistant prostate cancer (mCRPC), highlighting the need for new treatment options that can delay progression and improve OS [3] - Pluvicto is already approved for mCRPC and shows potential for earlier use in mHSPC, addressing significant unmet needs in hormone-sensitive prostate cancer [4][8] Group 3: Future Plans - Novartis plans to present the trial results at an upcoming medical meeting and will submit data for regulatory review in the second half of the year based on FDA feedback [5][7] - The company is expanding its portfolio of radioligand therapies (RLTs) for various advanced cancers and enhancing manufacturing capabilities to meet growing demand [9]

Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan. T ...

AVTL successfully completed IPORotterdam, the Netherlands, 02 June 2025 Today, we announce an update regarding the primary equity issue of our joint venture AVTL.AVTL has successfully completed its IPO. The issue price for the IPO was INR 235 per share which is at the top end of the previously announced price band. The size of the primary equity issue is INR 2,800 crore (approximately EUR 290 million). The board of AVTL issued an equivalent of 10.75% of new equity shares. As a result of the issuance of new ...

Core Viewpoint - Zealand Pharma has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog aimed at treating short bowel syndrome (SBS) in adults [1][2]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on developing innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two that have reached the market [12][13]. Product Development - Glepaglutide is designed as a liquid product for subcutaneous administration, intended to reduce or eliminate the need for parenteral support in SBS patients [4]. - The MAA submission is based on results from the pivotal Phase 3 trial (EASE-1) and interim results from ongoing long-term extension trials (EASE-2 and EASE-3) [2][3]. Clinical Trial Results - EASE-1 trial involved 106 SBS patients, showing that glepaglutide administered twice weekly significantly reduced weekly parenteral support volume by 5.13 liters compared to 2.85 liters in the placebo group [6]. - In EASE-1, 9 patients treated with glepaglutide achieved enteral autonomy, while no patients in the placebo group were able to discontinue parenteral support [6]. - EASE-2 continues to evaluate the efficacy of glepaglutide, with interim analyses indicating maintained or improved clinical responses [8]. Future Plans - Zealand Pharma plans to initiate the EASE-5 Phase 3 trial in the second half of 2025 to gather further confirmatory safety and efficacy data for regulatory submission in the U.S. [3][11].

WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 pm Geneva, Switzerland – June 2, 2025 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, is proud to announce that it will present Faben’s holograms for the first time at Lisbon NFC. There will be a live pe ...

Core Viewpoint - Vodafone Qatar has entered into a significant partnership with Nokia to modernize its network, enhancing 5G coverage, reliability, and service offerings across the country [1][2][3] Network Modernization - The agreement focuses on core modernization, expanded 5G capacity, and improved broadband to strengthen network reliability and efficiency [1][2] - Nokia's end-to-end technology will enable Vodafone Qatar to deliver faster and more secure 5G services, while also preparing the network for future innovations [2][3] Market Demand and Growth - Qatar's ICT sector is projected to grow at an annual rate of 8.5% through 2030, driving the demand for high-speed connectivity [4] - Vodafone Qatar aims to meet the increasing connectivity needs of consumers and businesses in this rapidly growing digital economy [4] Strategic Goals - The collaboration aligns with Qatar National Vision 2030, emphasizing Vodafone Qatar's commitment to digital transformation and the deployment of emerging technologies [5] - The integration of advanced fiber, mobile, and cloud capabilities will create a more agile and responsive network [5] Technological Advancements - Nokia's multi-cloud core software solutions will enhance Vodafone Qatar's network with automation, agility, and scalability [7][8] - The partnership includes a five-year managed services agreement for core operations, aimed at accelerating service rollouts and reducing costs [8] Future Outlook - The advancements from this collaboration are expected to set a new standard for digital transformation in Qatar and reinforce Nokia's position as a trusted technology partner [9]

Core Viewpoint - Sandoz has launched WYOST® and Jubbonti®, the first and only interchangeable FDA-approved denosumab biosimilars in the US, aimed at improving access to treatment for osteoporosis and cancer-related skeletal events [2][7]. Company Overview - Sandoz is a global leader in generic and biosimilar medicines, with a growth strategy focused on pioneering access for patients. The company recorded net sales of USD 10.4 billion in 2024 and has a portfolio of approximately 1,300 products [21]. Product Launch Details - WYOST® and Jubbonti® are approved for all indications of the reference medicines XGEVA® and Prolia®, respectively, and are integral to Sandoz's growth strategy in the biosimilar market [2][3]. - The products are designed to provide high-quality, cost-effective treatment options, enhancing patient access and affordability in the US [3][5]. Patient Impact - The introduction of these biosimilars is expected to significantly improve treatment access for over 10 million US adults aged 50 and older living with osteoporosis, as well as for approximately 330,000 individuals with bone metastases [5][6]. - Sandoz is providing comprehensive support resources for patients prescribed these medications, including reimbursement and financial assistance [4]. Regulatory Approval - Both WYOST® and Jubbonti® have been approved as interchangeable with their reference medicines, ensuring they have the same dosage form, route of administration, and dosing regimen [3][6].

Core Viewpoint - DNO ASA, a Norwegian oil and gas operator, has engaged Arctic Securities AS, DNB Carnegie, and Pareto Securities AS as Joint Bookrunners to arrange fixed income investor meetings, potentially leading to a new subordinated hybrid bond issue depending on market conditions and acceptable terms [1]. Company Overview - DNO ASA is an oil and gas operator based in Norway, active in the Middle East, North Sea, and West Africa [1]. - The company was founded in 1971 and is listed on the Oslo Stock Exchange [1]. - DNO ASA holds stakes in various onshore and offshore licenses at different stages of exploration, development, and production in regions including the Kurdistan region of Iraq, Norway, the United Kingdom, Côte d'Ivoire, and Yemen [1].

Core Insights - The SACHI Phase III study demonstrated that the combination of savolitinib and osimertinib significantly improves progression-free survival (PFS) in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) with MET amplification compared to chemotherapy [1][4][9] Study Overview - SACHI is a Phase III clinical trial focusing on the combination of savolitinib and osimertinib for treating patients with locally advanced or metastatic EGFR mutation-positive NSCLC with MET amplification after progression on first-line EGFR inhibitor therapy [2] Efficacy Results - In the intention-to-treat population, the median PFS was 8.2 months for the savolitinib plus osimertinib group versus 4.5 months for the chemotherapy group, with a hazard ratio (HR) of 0.34 [4] - The independent review committee assessed median PFS at 7.2 months for the combination therapy compared to 4.2 months for chemotherapy, with an HR of 0.40 [4] - The objective response rate (ORR) was 58% for the combination group compared to 34% for chemotherapy, and the disease control rate (DCR) was 89% versus 67% [5] Safety Profile - The combination therapy exhibited a tolerable safety profile, with treatment-emergent adverse events of Grade 3 or above occurring in 57% of patients in both the savolitinib plus osimertinib and chemotherapy groups [7][8] Regulatory Status - The Independent Data Monitoring Committee concluded that the study met its primary endpoint of PFS, leading to the conclusion of patient enrollment [9] - A New Drug Application (NDA) for the combination therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA) [9] Company Background - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [13]